Are you comfortable using durvalumab + tremelimumab in advanced HCC with portal vein thrombus, when these patients were not included in the HIMALAYA trial?
Community PollStarted
Although excluded from their respective clinical trials, do you utilize dual IO in patients with HCC with main portal vein thrombosis, Vp4?
19 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Medical Oncology · Mayo Clinic, Rochester
Answered on
Main portal vein thrombus (Vp4) has consistently been associated with poor prognosis, and prevalence can range from 20-44% in HCC within 1-3 years of diagnosis (Abdelhamed et al., PMID 39957750). Prior to 2020 and the advent of immunotherapy in the first line, median OS is around 2-5 months. In many...
Join for free or sign in to see the full answer